Foli Bio

Foli Bio is a private, pre-revenue biotech startup founded in 2021 and based in San Diego, CA. The company has developed Foli-seq™, a proprietary platform for non-invasive transcriptomic profiling of the gut using RNA from stool, aiming to unlock insights into gut health and disease. It is actively building collaborations with academic institutions and pharmaceutical companies to advance precision diagnostics and biomarker discovery for gastrointestinal conditions. The company is in a platform validation and partnership development stage.

Foli-seq™: A proprietary non-invasive platform that captures and analyzes host transcriptomic signals (RNA) from shed gut epithelial and immune cells in stool, combined with AI/ML analytics for molecular insights into gut mucosal biology.

Foli Bio competes with other companies developing non-invasive gut health diagnostics, such as those using microbial metagenomics (e.g., Seed Health, DayTwo) or host-focused proteomic/metabolomic assays. Its differentiation lies in its specific focus on host transcriptomics from stool, offering a direct readout of mucosal gene expression not captured by other methods.